Parker Waichman LLP Files Lawsuit on behalf of Florida Woman Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
PORT WASHINGTON, N.Y., Aug. 13, 2025 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits in New Jersey state court on behalf of victims who were prescribed Ozempic or Wegovy and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. Most recently, on August 7, 2025, the Firm filed a lawsuit on behalf of a 60-year Miami, Florida resident who developed NAION after taking Ozempic. See Delgado v. Novo Nordisk Inc., Docket No: MID-L-0047-25. To most efficiently litigate these cases, Parker Waichman LLP recently joined four other law firms and filed an application to the New Jersey Supreme Court to consolidate all New Jersey state lawsuits alleging permanent vision loss from use of Ozempic/Wegovy products in Middlesex County, New Jersey.
Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.
A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk.
Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness.
Parker Waichman LLP Fights for Victims Nationwide
'NAION is a devastating, and permanent, eye injury diagnosis. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable,' said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP.
Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages.
Free Case Review for Affected Individuals
If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice.
Contact Parker Waichman LLP Today
For a free consultation, call 1-800-YOUR-LAWYER ( 1-800-968-7529 ) or visit YourLawyer.com to learn more about your legal options and how to protect your rights.
About Parker Waichman LLP
Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Prod. Liab. Litig. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients.
Media Contact:
Parker Waichman LLP
Phone: 1-800-YOUR-LAWYER (1-800-968-7529)
Website: www.yourlawyer.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/parker-waichman-llp-files-lawsuit-on-behalf-of-florida-woman-alleging-development-of-irreversible-eye-condition-naion-after-taking-ozempic-302529163.html
SOURCE Parker Waichman LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Mounjaro weight-loss drug price to almost triple in UK
The price of popular weight-loss jab Mounjaro will nearly triple after the US-owned company equalised costs in markets across the globe. A month's supply of the highest doses of the 'King Kong' of weight loss medicine will rise from £122 to £330 - an increase of 170 per cent. At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight loss jab, via prescriptions from private online pharmacies, according to retailers. In June, the NHS offered Mounjaro to obese patients after health experts calculated from NHS England data that there were 97,500 patients who would benefit from the treatment. Mounjaro's owner Eli Lily said it would not raise the price paid by the NHS, and it was working with private healthcare providers to maintain access to the jab. The NHS said the price increase would not affect its commissioning of the medicine for people with obesity and type 2 diabetes. Eli Lilly launched Mounjaro in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The company said when it launched Mounjaro in the UK, it agreed to a list price "significantly below" that in its three other European markets to prevent delays in availability through the NHS. 'We are now aligning the list price more consistently,' a spokesperson said. The move reflects how the pharmaceutical industry is navigating policy changes in the US, by far its most lucrative market. It comes after Donald Trump's administration complained about 'foreign freeloaders' who rely on the US to pay more for medicine. The US pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. Mr Trump says he wants to narrow this gap to stop Americans from being "ripped off". In the UK, the NHS was told to offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. Over the next three years, about 240,000 patients are expected to be eligible for the treatment. It came after the National Institute for Health and Care Excellence (Nice) warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. The new 'quality standard' from Nice said NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. Weight-loss injections, also known as GLP-1 receptor agonists, work by mimicking the natural hormone which regulates blood sugar, appetite and digestion.
Yahoo
4 hours ago
- Yahoo
Lilly raises UK obesity shot price as Trump pressures pharma
(Bloomberg) — Eli Lilly & Co. is raising the list price for its obesity shot in the UK by as much as 170%, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans. The current list price in the UK for Lilly's Mounjaro ranges from £92 ($124.89) to £122 a month, depending on the dose. This will increase to between £133 and £330 from Sept. 1, with the US drugmaker saying it aims to bring rates in line with other countries. Trump sent letters to 17 of the world's largest drugmakers earlier this month, including Lilly and Novo Nordisk A/S, which makes the competing shot Wegovy, insisting they lower what they charge Medicaid in the US for existing drugs. He gave the companies 60 days to comply, saying he wants companies to negotiate harder with 'foreign freeloading nations' who pay less for their medicines. Lilly said the increase follows a review that looked to address pricing inconsistencies. The UK was one of the first countries where Mounjaro was introduced, with rates 'significantly below the European average to prevent delays' in availability via the National Health Service, the company added. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, Lilly are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' it said. Affordability Concerns The new list price is still well below the level in the US, where it costs over $1,000 a month. Still, the higher prices raised concerns in online forums from patients who say the drug will be unaffordable for them. Patients in the UK usually get most medicines on the National Health Service for a set prescription price of £9.90. However, obesity drugs have only just started to be rolled out on the NHS and the criteria for access are stringent. So far, the majority of patients who access the weight-loss shots have been doing so privately. The actual price that these patients pay is likely to be well below the list price, because Lilly negotiated commercial agreements with private providers. Still, those providers are likely to face difficult decisions on how much to pass on any price increase to patients. Pharmacies like Walgreens Boots Alliance Inc.'s Boots and Superdrug, as well as online providers like Juniper and Voy that have focused on weight-loss drugs, have benefited from the rush for obesity shots. If patients are unable to afford more expensive Mounjaro, they may also switch to Novo's Wegovy. Novo has not yet announced a similar increase in price for its obesity drug. While the list price has increased, Lilly said it is working with private providers to maintain access for patients. Separately, the company reached an agreement with the NHS to ensure continued supply and patient access. —With assistance from Madison Muller. (Updates with more detail on pharmacies selling the shots, from paragraph nine) ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Something Inside Your Gut Could Be Like a Natural Ozempic
Ozempic and drugs like it have done wonders for weight loss by mimicking the natural hormone GLP-1 (glucagon-like peptide-1), which helps control blood sugar and appetite. Now a new study shows how gut microbe byproducts could have the same effect. Enteroendocrine cells (EECs) in the gut are responsible for producing natural GLP-1, and recent research has suggested a reduced number of EECs and lower GLP-1 production could be helping to drive obesity. Using tests on rats and mini-guts grown in the lab (known as organoids), researchers from Marshall University in the US have now confirmed a link between fewer EECs and obesity – and found a way to get the gut to make up the shortfall. Related: "This points to a potential therapeutic strategy that leverages the gut microbes to improve metabolic outcomes in obesity," says biochemist Alip Borthakur of the Department of Clinical & Translational Sciences at Marshall University. The researchers turned to supplements of the amino acid tryptophan to fix the EEC problem. Tryptophan was already known to promote good gut health, in part through a metabolite (or biological byproduct) called indole. What the team was able to show in their work was that tryptophan and indole could form a production line to generate new EECs, and from there, more GLP-1. In other words, it promoted a more natural way of getting the same effect as a dose of Ozempic. Tryptophan is found in foods such as poultry, eggs, cheese, and certain seeds, and the thinking is that dietary supplements or probiotics of some kind could be used to drop the amino acid into the gut and start the necessary chemical chain reaction. "Our findings suggest that microbial metabolites derived from dietary tryptophan can reverse obesity-associated reductions in hormone-secreting gut cells," says Borthakur. The researchers were also able to identify a specific cell receptor, the aryl hydrocarbon receptor (AhR), through which this process occurs. That gives researchers a particular target to aim at. Actual treatments are still a long way off, but these initial findings are promising. Ozempic is one of a class of drugs known as GLP-1 receptor antagonists, used to treat type 2 diabetes as well as obesity. However, these treatments do come with side effects, and it would be preferable for our bodies to produce GLP-1 more naturally. That's part of the motivation for studies like this. In recent years, other teams of scientists have identified ways to tweak gut bacteria and adapt our diets to try and boost GLP-1 production in the body. One of the next steps will be to move these experiments out of rats and organoids and into actual human beings. While the lab tests carried out here do of course provide useful pointers for researchers, the processes and reactions inside people could vary in certain ways – which further studies can look into. "The molecular players and signaling pathways involved in the regulation of EEC differentiation could be different in the normal and obese conditions," write the researchers in their published paper. The research has been published in the International Journal of Molecular Sciences. Related News New Vaccine For Two Deadly Cancers Shows Promise in Clinical Trial Scientists Identify How Young Blood Reverses Aging in Human Skin Cells Vegetarian Diets Can Slash Cancer Risk by Up to 45%, Large Study Finds Solve the daily Crossword
